SÜLFAMETOKSAZOLÜN ENDOTEL VE FİBROBLAST HÜCRELERİ ÜZERİNDEKİ ETKİLERİNİN DEĞERLENDİRİLMESİ

Abstract

Amaç: Sülfametoksazol (SMX), bakteriyel enfeksiyonların tedavisinde kullanılan bir sülfonamid türevi ilaçtır. SMX sadece enfeksiyon tedavisinde değil, aynı zamanda doku rejenerasyonu ve yara iyileşmesindeki olası rolüyle de potansiyel terapötik uygulama alanları ilgi uyandırmaktadır. Bu çalışmada SMX’in fibroblast ve endotel hücrelerinin canlılığı, migrasyonu ve kollajen gen ekspresyonu üzerindeki etkilerinin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Bu çalışmada, endotel hücre hattı olarak HUVEC ve fibroblast hücre hattı olarak ise L929 kullanıldı. Hücre canlılığı MTT testi ile, migrasyon inhibisyonu yara iyileşme testi ile ve COL1A1 gen ekspresyonu ise qRT-PCR yöntemi ile değerlendirildi. Sonuç ve Tartışma: SMX’in, endotel ve fibroblast hücrelerinde yara iyileşmesini destekleyecek bazı olumlu etkiler gösterdiği ancak bazı konsantrasyonların hücresel süreçleri olumsuz etkileyebileceği bulundu. SMX’in kullanıldığı terapötik alanlarının genişletilebilmesi için daha ayrıntılı in vitro araştırmalara ihtiyaç duyulmaktadır.

Keywords

• Endotelyal hücre
• fibroblast hücresi
• sülfametoksazol
• yara iyileşmesi

EVALUATION OF THE EFFECTS OF SULFAMETHOXAZOLE ON ENDOTHELIAL AND FIBROBLAST CELLS

Abstract

Objective: Sulfamethoxazole (SMX) is a sulfonamide derivative drug used in the treatment of bacterial infections. The potential role of SMX not only in the treatment of infections but also in tissue regeneration and wound healing has aroused interest in its potential therapeutic applications. In this study, we aimed to determine the effects of SMX on fibroblast and endothelial cell viability, migration and collagen gene expression. Material and Method: In this study, HUVEC was used as endothelial cell line and L929 as fibroblast cell line. Cell viability was evaluated by MTT assay, migration inhibition by wound healing assay and COL1A1 gene expression by qRT-PCR method. Result and Discussion: SMX was found to show some positive effects on endothelial and fibroblast cells to promote wound healing, but some concentrations may negatively affect cellular processes. More detailed in vitro research is needed to expand the therapeutic areas in which SMX is used.

Keywords

• Endothelial cell
• fibroblast cell
• sulfamethoxazole
• wound healing

References

1. 1. Masters, P.A., O’Bryan, T.A., Zurlo, J., et al. (2003). Trimethoprim-sulfamethoxazole revisited. Archives of Internal Medicine, 163(4), 402-410. [Crossref]
2. 2. Hong, Y.L., Hossler, P.A., Calhoun, D.H., et al. (1995). Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrobial Agents and Chemotherapy, 39(8), 1756-1763. [Crossref]
3. 3. Zarou, M.M., Vazquez, A., Vignir Helgason, G. (2021). Folate metabolism: A re-emerging therapeutic target in haematological cancers. Leukemia, 35(6), 1539-1551. [Crossref]
4. 4. UpToDate Web Site. https://www.uptodate.com. Accessed date: 19.12.2024.
5. 5. Kim, H.Y., Kang, H.G., Kim, H.M., et al. (2023). Anti-tumor activity of trimethoprim-sulfamethoxazole against melanoma skin cancer through triggering allergic reaction and promoting immunity. International Immunopharmacology, 123, 110742. [Crossref]
6. 6. Gupta, R., Kazmi, I., Afzal, M., et al. (2013). Combination of sulfamethoxazole and selenium in anticancer therapy: A novel approach. Molecular and Cellular Biochemistry, 384(1-2), 279-285. [Crossref]
7. 7. Abdelgawad, M.A., Bukhari, S.N.A., Musa, A., et al. (2022). New sulfamethoxazole derivatives as selective carbonic anhydrase IX and XII inhibitors: Design, synthesis, cytotoxic activity and molecular modeling. Pharmaceuticals, 15(9), 1134. [Crossref]
8. 8. Bowen, A.C., Carapetis, J.R., Currie, B.J., et al. (2017). Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for skin and soft tissue infections including impetigo, cellulitis, and abscess. Open Forum Infectious Diseases, 4(4), ofx232. [Crossref]

9. 9. Van Hove, L., Hoste, E. (2022). Activation of fibroblasts in skin cancer. The Journal of Investigative Dermatology, 142(4), 1026-1031. [Crossref]
10. 10. Mascharak, S., desJardins-Park, H.E., Longaker, M.T. (2020). Fibroblast heterogeneity in wound Healing: Hurdles to clinical translation. Trends in Molecular Medicine, 26(12), 1101-1106. [Crossref]
11. 11. Kendall, R.T., Feghali-Bostwick, C.A. (2014). Fibroblasts in fibrosis: Novel roles and mediators. Frontiers in Pharmacology, 27, 5. [Crossref]
12. 12. Laberge, A., Arif, S., Moulin, V.J. (2018). Microvesicles: Intercellular messengers in cutaneous wound healing. Journal of Cellular Physiology, 233(8), 5550-5563. [Crossref]
13. 13. Eming, S.A., Brachvogel, B., Odorısıo, T., et al. (2007). Regulation of angiogenesis: Wound healing as a model. Progress in Histochemistry and Cytochemistry, 42(3), 115-170. [Crossref]
14. 14. Fujita, T., Yuki, T., Honda, M. (2024). The construction of a microenvironment with the vascular network by co-culturing fibroblasts and endothelial cells. Regenerative Therapy, 25, 138-146. [Crossref]
15. 15. Tan, Y., Zhang, M., Kong, Y., et al. (2024). Fibroblasts and endothelial cells interplay drives hypertrophic scar formation: Insights from in vitro and in vivo models. Bioengineering & Translational Medicine, 9(2), 20. [Crossref]
16. 16. Kaçaroğlu, D. (2024). Assessing the effects of lornoxicam and dexketoprofen on mouse fibroblast cells. Lokman Hekim Health Sciences, 181-187. [Crossref]
17. 17. Abbaszadegan, A., Gholami, A., Ghahramani, Y., et al. (2015). Antimicrobial and cytotoxic activity of Cuminum cyminum as an intracanal medicament compared to chlorhexidine gel. Iranian Endodontic Journal, 11(1), 44.
18. 18. Dragostin, O.M., Sama, S.K., Lupascu, F., et al. (2015). Development and characterization of novel films based on sulfonamide-chitosan derivatives for potential wound dressing. International Journal of Molecular Sciences, 16(12), 29843-29855. [Crossref]
19. 19. Dumitriu, R.P., Profire, L., Nita, L.E., et al. (2015). Sulfadiazine-chitosan conjugates and their polyelectrolyte complexes with hyaluronate destined to the management of burn wounds. Materials, 8(1), 317-338. [Crossref]
20. 20. Altoé, L.S., Alves, R.S., Sarandy, M.M., et al. (2019). Does antibiotic use accelerate or retard cutaneous repair? A systematic review in animal models. PLoS One, 14(10), e0223511. [Crossref]
21. 21. Mathew-Steiner, S.S., Roy, S., Sen, C.K. (2021). Collagen in wound healing. Bioengineering. 8(5), 63. [Crossref]
22. 22. Hayashi, M., Nomoto, S., Hishida, M., et al. (2014). Identification of the collagen type 1 alpha 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer. 14(1),108. [Crossref]
23. 23. Li, X., Sun, X., Kan, C., et al. (2022). COL1A1: A novel oncogenic gene and therapeutic target in malignancies. Pathology, Research and Practice. 236, 154013. [Crossref]
24. 24. Rodrigues, M., Kosaric, N., Bonham, C.A., et al. (2019). Wound healing: A cellular perspective. Physiological Reviews, 99(1), 665-706. [Crossref]
25. 25. Tonnesen, M.G., Feng, X., Clark, R.A. (2000). Angiogenesis in wound healing. Journal of Investigative Dermatology Symposium Proceedings, 5(1), 40-46. [Crossref]
26. 26. Page-McCaw, A., Ewald, A.J., Werb, Z. (2007). Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews Molecular Cell Biology, 8(3), 221-233. [Crossref]
27. 27. Hynes, R.O. (2002). Integrins: Bidirectional, Allosteric Signaling Machines. Cell, 110(6), 673-687. [Crossref]
28. 28. Massagué, J. (2012). TGFβ signalling in context. Nature Reviews Molecular Cell Biology, 13(10), 616-630. [Crossref]